Aptose Biosciences Inc (APS) - Total Liabilities
Based on the latest financial reports, Aptose Biosciences Inc (APS) has total liabilities worth CA$25.79 Million CAD (≈ $18.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aptose Biosciences Inc cash conversion from operations to assess how effectively this company generates cash.
Aptose Biosciences Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Aptose Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Aptose Biosciences Inc to evaluate the company's liquid asset resilience ratio.
Aptose Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Aptose Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yunji Inc
NASDAQ:YJ
|
USA | $248.09 Million |
|
Tartana Minerals Ltd
AU:TAT
|
Australia | AU$7.54 Million |
|
Nichols
LSE:NICL
|
UK | GBX42.61 Million |
|
zSpace, Inc. Common stock
NASDAQ:ZSPC
|
USA | $33.14 Million |
|
Simble Solutions Ltd
AU:SIS
|
Australia | AU$1.22 Million |
|
Foresight Solar Fund Ltd
LSE:FSFL
|
UK | GBX1.94 Million |
|
Terregra Asia Energy PT
JK:TGRA
|
Indonesia | Rp196.83 Billion |
|
Gratomic Inc
V:GRAT
|
Canada | CA$7.10 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Aptose Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Aptose Biosciences Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptose Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptose Biosciences Inc (1996–2024)
The table below shows the annual total liabilities of Aptose Biosciences Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$14.67 Million ≈ $10.61 Million |
-7.68% |
| 2023-12-31 | CA$15.89 Million ≈ $11.49 Million |
+19.60% |
| 2022-12-31 | CA$13.29 Million ≈ $9.61 Million |
+60.28% |
| 2021-12-31 | CA$8.29 Million ≈ $6.00 Million |
+12.82% |
| 2020-12-31 | CA$7.35 Million ≈ $5.31 Million |
+12.17% |
| 2019-12-31 | CA$6.55 Million ≈ $4.74 Million |
+134.85% |
| 2018-12-31 | CA$2.79 Million ≈ $2.02 Million |
+58.02% |
| 2017-12-31 | CA$1.76 Million ≈ $1.28 Million |
+33.92% |
| 2016-12-31 | CA$1.32 Million ≈ $953.42K |
-22.56% |
| 2015-12-31 | CA$1.70 Million ≈ $1.23 Million |
-15.33% |
| 2014-12-31 | CA$2.01 Million ≈ $1.45 Million |
+14.09% |
| 2013-12-31 | CA$1.76 Million ≈ $1.27 Million |
-32.31% |
| 2012-12-31 | CA$2.60 Million ≈ $1.88 Million |
+119.38% |
| 2011-12-31 | CA$1.19 Million ≈ $858.27K |
-56.00% |
| 2010-12-31 | CA$2.70 Million ≈ $1.95 Million |
-81.49% |
| 2009-12-31 | CA$14.57 Million ≈ $10.54 Million |
-6.31% |
| 2008-12-31 | CA$15.55 Million ≈ $11.25 Million |
+13.01% |
| 2007-12-31 | CA$13.76 Million ≈ $9.95 Million |
+8.07% |
| 2006-12-31 | CA$12.73 Million ≈ $9.21 Million |
+11.71% |
| 2005-12-31 | CA$11.40 Million ≈ $8.24 Million |
0.00% |
| 2004-12-31 | CA$11.40 Million ≈ $8.24 Million |
+166.57% |
| 2003-12-31 | CA$4.28 Million ≈ $3.09 Million |
+90.40% |
| 2002-12-31 | CA$2.25 Million ≈ $1.62 Million |
0.00% |
| 2001-12-31 | CA$2.25 Million ≈ $1.62 Million |
-41.13% |
| 2000-12-31 | CA$3.81 Million ≈ $2.76 Million |
+58.39% |
| 1999-12-31 | CA$2.41 Million ≈ $1.74 Million |
+173.12% |
| 1998-12-31 | CA$881.66K ≈ $637.78K |
+16.75% |
| 1997-12-31 | CA$755.18K ≈ $546.29K |
-5.38% |
| 1996-12-31 | CA$798.14K ≈ $577.36K |
-- |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more